Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer-Reference-Cited by-同舟云学术

Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer

Published:2015-04-24 Issue:8 Volume:55 Page:888-898
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Rodríguez-Vera Leyanis¹,Ramos-Suzarte Mayra²,Fernández-Sánchez Eduardo³,Soriano Jorge Luis⁴,Guitart Concepción Peraire⁵,Hernández Gilberto Castañeda⁶,Jacobo-Cabral Carlos O.⁶,de Castro Suárez Niurys¹,Codina Helena Colom⁵

Affiliation:

1. Laboratory of Pharmacokinetic, Department of Pharmacology & Clinical Pharmacy, Institute of Pharmacy & Foods; University of Havana; Havana Cuba

2. Center of Molecular Immunology; Havana Cuba

3. Center for Biological Evaluation and Research, Institute of Pharmacy & Foods; University of Havana; Havana Cuba

4. Hermanos Ameijeiras Hospital; Havana Center; Havana Cuba

5. Pharmacy and Pharmaceutical Technology Department, School of Pharmacy; University of Barcelona; Barcelona Spain

6. Department of Pharmacology; CINVESTAV-IPN; Mexico City Mexico

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.496/fullpdf

Reference39 articles.

1. h-R3;Crombet;Drugs Future.,2003

2. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity;Mateo;Immunotechnology.,1997

3. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis;Viloria-Petit;Cancer Res.,2001

4. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer;Crombet;J Immunother.,2003

5. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients;Crombet;J Clin Oncol.,2004

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients;British Journal of Clinical Pharmacology;2023-12-29

2. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients;Clinical Pharmacokinetics;2023-07-13

3. GCD-PKAug: A Gradient Consistency Discriminator-Based Augmentation Method for Pharmacokinetics Time Courses;Communications in Computer and Information Science;2023

4. Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease;Pharmaceutics;2020-11-26

5. Automatic Parallelization of Probabilistic Models with Varying Load Imbalance;2020 20th IEEE/ACM International Symposium on Cluster, Cloud and Internet Computing (CCGRID);2020-05